Zhanjuan Chen | New Drug Discovery | Applied Scientist Award

Published on by Applied Scientist

Prof. Zhanjuan Chen | New Drug Discovery | Applied Scientist Award

Professor at Hainan Medical University, China

Professor Zhanjuan Chen, currently serving at Hainan Medical University, is an accomplished academic with focused research expertise in the pathogenesis and drug screening for cancer and related diseases such as pulmonary hypertension. Her pioneering investigations have identified MEIS1 and LDHA as potential therapeutic targets for acute myeloid leukemia and pulmonary hypertension, respectively. Her contributions are grounded in both traditional Chinese medicine and modern biomedical science, demonstrating a unique interdisciplinary strength. Professor Chen is leading the development of Callicarpa Tissue-Regenerating Gel, an innovative treatment for chronic non-healing wounds. Her scientific output includes two SCI-indexed articles, one with 17 citations, as well as one book publication, a patent, and multiple collaborative R&D efforts. A member of the Chinese Pharmacological Society and the Hainan Provincial Laboratory Animal Science Association, she has actively contributed to academic and professional communities. Her efforts bridge theoretical research and translational application, demonstrating significant potential in therapeutic development. Professor Chen has completed and is continuing several high-impact research projects and has gained valuable experience through industry collaborations. With a steadfast commitment to innovation and patient care, her work aligns well with the mission of the Applied Scientist Awards. She stands as a strong candidate for recognition based on her impactful contributions to science and medicine.

Professional Profile

Education

Professor Zhanjuan Chen’s academic journey reflects her unwavering dedication to biomedical science. She pursued her higher education with a strong emphasis on pharmacology, traditional Chinese medicine, and translational oncology. Although specific institutional details of her academic degrees are not provided in the nomination form, her academic foundation is clearly rooted in multidisciplinary and clinically oriented research, evidenced by her current academic role and her published outputs. Her studies prepared her extensively in molecular biology, pathogenesis of chronic diseases, pharmacodynamics, and drug discovery techniques. Her background integrates both conventional research methodologies and cutting-edge approaches, such as high-throughput screening and mechanistic investigations of disease pathways. Through her academic training, she acquired expertise in understanding the molecular underpinnings of cancer and pulmonary diseases, allowing her to formulate novel hypotheses and experimental strategies. Additionally, her immersion in traditional Chinese pharmacology has provided her with a holistic outlook toward therapeutic discovery, particularly in the development of tissue-regenerating formulations. Her educational trajectory is also complemented by continued scholarly engagement, including contributions to scientific publications and patents. Professor Chen’s education has laid a strong intellectual and practical foundation for her impactful research career, positioning her well to address current challenges in oncology and pharmacology with innovative, evidence-based solutions.

Professional Experience

Professor Zhanjuan Chen has accumulated significant experience in both academic and translational research environments. As a faculty member at Hainan Medical University, she has led multiple research initiatives that combine experimental pharmacology with clinical application. Her academic appointments reflect a career trajectory marked by continuous advancement and increasing research responsibility. Notably, her role as principal investigator for projects such as “Astragalin Regulates Proliferation of Acute Myeloid Leukemia Cells by Targeted Inhibition of MEIS1 Protein” underscores her leadership in the field of targeted cancer therapy. She is also the innovator behind the Callicarpa Tissue-Regenerating Gel, a formulation developed to promote healing in chronic wounds—a major challenge in geriatric and diabetic care. Beyond her institutional duties, Professor Chen has collaborated with industry partners on the development of Zizhu Shengji Gel, showcasing her ability to translate laboratory findings into real-world healthcare solutions. Her professional engagements extend to managing patents, publishing research articles, and authoring a scientific book. Her affiliations with professional bodies further strengthen her academic presence. In every role, Professor Chen has demonstrated scientific rigor, mentorship, and a passion for innovation. Her broad experience, spanning research, development, and clinical application, equips her with a unique skillset to contribute meaningfully to the scientific community.

Research Interest

Professor Chen’s research interests center on elucidating the molecular pathogenesis of cancer and cancer-like diseases, particularly pulmonary hypertension, and discovering therapeutic agents through both conventional and traditional medical approaches. Her work is heavily influenced by the integration of modern biomedical techniques with traditional Chinese pharmacology. Her early contributions included identifying MEIS1 as a therapeutic target for acute myeloid leukemia, which she continues to explore through targeted therapeutic strategies using compounds like astragalin. She has also identified LDHA as a critical regulatory target in pulmonary hypertension, offering new hope for treatment development in this complex disease. Currently, her research expands into regenerative medicine, exemplified by her work on Callicarpa Tissue-Regenerating Gel, which bridges pharmacological insights with practical wound care solutions. She is also engaged in the R&D of Zizhu Shengji Gel, an innovative traditional Chinese medicine for wound healing. These interests position her at the forefront of translational medicine and drug innovation. Her ability to connect basic molecular discoveries to clinical and therapeutic applications is a distinctive strength. Her research vision is to continue combining molecular biology, pharmacology, and traditional medicine to deliver accessible, effective treatments for some of today’s most challenging medical conditions.

Research Skills

Professor Zhanjuan Chen possesses a robust skill set that spans multiple domains of biomedical research. Her core competencies include target discovery using molecular biology techniques, pharmacological screening, disease modeling, and translational application. She is adept in methodologies such as Western blotting, immunohistochemistry, gene expression profiling, and cellular proliferation assays. Her ability to evaluate drug efficacy, particularly natural compounds like astragalin, is enhanced by her skills in in vitro and in vivo disease models. Additionally, her knowledge in formulating traditional Chinese medicine into modern therapeutic agents—like tissue-regenerating gels—exemplifies her interdisciplinary capabilities. Her patent and book publication demonstrate proficiency in scientific writing and product development. Professor Chen is also experienced in project management and collaborative R&D, coordinating with academic and industrial stakeholders to move innovations from the bench to the bedside. Her skills are continuously refined through her active engagement in research projects and industry partnerships. Furthermore, her understanding of regulatory frameworks and translational research pipelines ensures that her discoveries are positioned for clinical applicability. These capabilities make her not just a scientist but a comprehensive innovator in healthcare. She combines scientific rigor with creativity, making her research both impactful and implementable in real-world clinical settings.

Awards and Honors

While specific awards and honors were not detailed in the application, Professor Zhanjuan Chen’s academic and research trajectory clearly demonstrates the caliber worthy of prestigious recognition. Her identification of MEIS1 and LDHA as key therapeutic targets represents a significant advancement in the fields of oncology and pulmonary medicine. The development of her Callicarpa Tissue-Regenerating Gel also highlights her contribution to regenerative medicine, offering a new avenue for treating chronic, non-healing wounds. These innovations underline her eligibility for honors such as the Best Researcher Award or Excellence in Innovation. Her selection as a principal investigator on multiple projects, including industry collaborations, speaks to the trust placed in her expertise by peers and stakeholders alike. Publishing in SCI-indexed journals, authoring a book, and patenting her inventions all reflect professional acknowledgment of her work’s quality and relevance. Moreover, her memberships in national academic societies signify her integration into scholarly networks that recognize her contributions. Though formal accolades may not yet be numerous, the tangible impact of her work—on science, clinical practice, and traditional medicine modernization—places her in strong contention for distinguished recognition in applied science domains.

Conclusion

Professor Zhanjuan Chen exemplifies the ideal candidate for the Applied Scientist Award. Her work seamlessly integrates cutting-edge biomedical research with the time-tested principles of traditional Chinese medicine, reflecting a unique and impactful research philosophy. From identifying novel therapeutic targets to formulating new medicinal gels, she has consistently demonstrated innovation, rigor, and a commitment to improving human health. Her ability to bridge the gap between fundamental science and clinical application ensures that her work not only advances knowledge but also delivers real-world solutions. Through her collaborations with academic institutions and industry partners, she has expanded the reach and relevance of her research. Her dual expertise in modern molecular pharmacology and traditional healing systems places her at the nexus of innovation and tradition—an increasingly valuable perspective in global healthcare. Professor Chen’s career reflects sustained excellence and growth, making her a role model for interdisciplinary research and a strong ambassador for translational science. Recognizing her achievements with an award would not only honor her contributions but also inspire continued progress in applied medical research. She stands as a testament to the transformative potential of integrating science with tradition to solve pressing medical challenges.

Publications Top Notes

  • Title: Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial‐To‐Mesenchymal Transition
    Authors: Maozhong Yao, Keyan Zhong, Xinbin Zheng, Zhaoxin Yang, Chunying Li, Yong Gu, Zhanjuan Chen
    Year: 2025

  • Title: MEIS1 and its Potential as a Cancer Therapeutic Target (Review)
    Authors: Maozhong Yao, Yong Gu, Zhaoxin Yang, Keyan Zhong, Zhanjuan Chen
    Year: 2021

Bonewendé Mohamed Belemlilga | Drug Development | Best Researcher Award

Published on by Applied Scientist

Dr. Bonewendé Mohamed Belemlilga | Drug Development | Best Researcher Award

Reseacher at Institut de Recherche en Sciences de la Sante, Burkina Faso

Bonewendé Mohamed BELEMLILGA is a distinguished Burkinabè research associate specializing in Animal Pharmacology and Physiology at the Institut de Recherche en Sciences de la Santé (IRSS/CNRST). With a career marked by extensive contributions to ethnopharmacology, phytomedicine development, and preclinical drug evaluation, he has become a central figure in advancing traditional medicine through scientific validation in Burkina Faso and across West Africa. His leadership extends to key roles such as Head of the Research and Evaluation Department at IRSS and editorial board member for the Science de la Santé journal. He is also actively involved in national research strategy formulation, having served on committees crafting the CNRST’s 2025–2029 strategic research plan. Dr. BELEMLILGA’s expertise is further reflected in over 50 peer-reviewed publications focusing on pharmacological studies, toxicity assessments, and the pharmacodynamic properties of medicinal plants. His dedication to bridging traditional knowledge and modern science has led him to coordinate and participate in several national and international research projects, educational programs, and clinical investigations. With a solid background in both experimental research and academic supervision, he represents a dynamic blend of scholarly depth, technical skill, and visionary research leadership in African health science innovation.

Professional Profile

Education

Dr. Bonewendé Mohamed BELEMLILGA pursued his higher education at the University of Ouagadougou, where he demonstrated a consistent commitment to excellence in health and biological sciences. He obtained his Bachelor’s degree in Biological Sciences in 2007, followed by a Master’s degree in Biological Sciences with a specialization in Animal Biology and Physiology in 2008. He then advanced to complete a DEA (Diplôme d’Études Approfondies) in Applied Pharmacology and Toxicology from the UFR-SDS in 2011, achieving honors for his academic performance. His doctoral studies culminated in a Ph.D. in Applied Pharmaceutical Sciences, with a specialization in Applied Pharmacology, awarded by the Doctoral School of Health in 2019. His dissertation focused on the pharmacological and phytochemical properties of Saba senegalensis, a plant traditionally used to treat parasitic infections. This strong academic foundation equipped Dr. BELEMLILGA with the skills necessary for rigorous scientific research in pharmacology and ethnomedicine. In addition, his multilingual proficiency in French and English and his strong computer skills enhance his ability to operate effectively in both national and international academic settings. His academic path reflects a deep-seated dedication to public health through biomedical innovation.

Professional Experience

Dr. BELEMLILGA’s professional journey is marked by a rich tapestry of research, teaching, and leadership roles. Since 2020, he has served as a research associate in Animal Pharmacology-Physiology at IRSS/CNRST, while also heading the Research and Evaluation Department since January 2024. He has been instrumental in multiple strategic planning committees, including the Commission for Research and Innovation, the CNRST’s disciplinary board, and the drafting of national research strategies for 2025–2029. As a temporary lecturer at Université Saint Thomas d’Aquin, he has also been active in academic mentorship, supervising multiple master’s and doctoral theses. His expertise has been recognized internationally, exemplified by training certifications in Good Clinical Practice (ICH E6 R2), clinical research, and laboratory quality systems. Dr. BELEMLILGA has coordinated numerous clinical and pharmacological projects, notably on phytomedicines for gastrointestinal and respiratory illnesses. His fieldwork includes internships and collaborative research across France, Côte d’Ivoire, and Ghana. He is a founding member of the Société de Pharmacologie et Toxicologie du Burkina (SOPHATOX-B) and a contributor to numerous workshops and training programs. Through these roles, he has demonstrated an unwavering commitment to evidence-based health science rooted in traditional knowledge.

Research Interest

Dr. BELEMLILGA’s research interests lie at the dynamic intersection of ethnopharmacology, parasitology, toxicology, and pharmacognosy. His central scientific pursuit focuses on validating traditional medicinal practices by elucidating the pharmacological properties of plant-based therapies used in Burkina Faso and West Africa. With a special emphasis on parasitic diseases and gastrointestinal infections, he has conducted extensive in vitro and in vivo experiments to evaluate antipyretic, anti-inflammatory, analgesic, antioxidant, and anthelmintic activities of natural plant extracts. Plants like Saba senegalensis, Balanites aegyptiaca, and Gomphrena serrata are frequently featured in his studies. His research also involves toxicological screening to ensure the safety of phytomedicines intended for human or veterinary use. In recent years, Dr. BELEMLILGA has expanded his interest into clinical trial design, especially in the context of plant-based antimalarial and anti-parasitic formulations. He is also actively engaged in capacity building and promoting best practices in traditional medicine production and usage. His research aims to bridge the gap between indigenous healing systems and modern biomedicine, contributing to global health initiatives through culturally grounded scientific innovation.

Research Skills

Dr. BELEMLILGA has cultivated a robust set of interdisciplinary research skills that underpin his expertise in ethnopharmacology and biomedical sciences. His core competencies include phytochemical screening, bioassay-guided fractionation, pharmacodynamic and toxicological testing of natural extracts, and the standardization of phytomedicines. He is well-versed in both qualitative and quantitative experimental techniques, ranging from in vivo efficacy trials to molecular analytical methods such as chemical profiling via molecular networking. His hands-on experience includes high-level laboratory procedures, animal experimentation, and clinical trial coordination adhering to international GCP standards. Dr. BELEMLILGA is proficient in project management, having led and contributed to multiple funded research initiatives across Africa and Europe. He is also skilled in academic writing and peer-review processes, serving as an excellent reviewer for several scientific journals. As a scientific trainer and lecturer, he has transferred knowledge to students and health professionals through numerous workshops, including those hosted by the WHO-TDR and local universities. His ability to design, implement, and evaluate complex biomedical studies places him at the forefront of research promoting safe and effective traditional medicine integration.

Awards and Honors

Dr. BELEMLILGA’s contributions have been acknowledged through numerous awards, certifications, and prestigious appointments. In 2022 and 2023, he was recognized with the Certificate of Excellence for his role as a peer reviewer in leading scientific journals. His leadership in the IRSS/CNRST has earned him positions on key national committees, such as the Commission for Research and Innovation and the Editorial Board of Sciences et Technique. He has received multiple certifications from renowned organizations like WHO-TDR and the Global Health Network, reflecting international recognition of his expertise in clinical research and pharmacological evaluation. As a founding member of SOPHATOX-B and a certified trainer in ethnopharmacology, Dr. BELEMLILGA has significantly contributed to capacity-building initiatives across West Africa. His scientific publications have garnered citations and respect within the fields of traditional medicine and drug development. His work has not only influenced policy frameworks in Burkina Faso but has also enhanced the global visibility of African medicinal plant research. These accolades underscore his commitment to excellence, collaboration, and innovation in public health research and education.

Conclusion

Dr. Bonewendé Mohamed BELEMLILGA exemplifies a new generation of African researchers bridging traditional medicine with modern pharmacological science. With a career grounded in rigorous education and enriched by international collaborations, he continues to push the boundaries of phytomedicine research in West Africa. His work has had a tangible impact on both policy and practice, particularly in the validation and clinical assessment of indigenous medicinal formulations. As a research associate, academic mentor, strategic planner, and scientific communicator, he has made enduring contributions to the biomedical landscape in Burkina Faso and beyond. His dedication to interdisciplinary research, ethical scientific practice, and public health empowerment demonstrates a holistic vision for African health innovation. Through an impressive portfolio of publications, funded projects, and leadership roles, Dr. BELEMLILGA is shaping the future of pharmacological research rooted in cultural relevance and scientific integrity. His continued efforts promise to yield new therapies, foster research capacity, and inspire the next generation of scholars committed to sustainable, evidence-based healthcare solutions in Africa and globally.

Publications Top Notes

  1. chemical analysis by molecular networking methods on extracts of saba senegalensis and its anthelmintic activity on caenorhabditis elegans
    Authors: Mohamed B. Belemlilga, Hazrina Hazni, Aristide Traore, Indira Dennemont, Sébastien Pomel, Sandrine Cojean, Mehdi A. Beniddir, Sylvin Ouedraogo, Christian Bories, Philippe M. Loiseau
    Year: 2025

  2. evaluation of anti-inflammatory activities and acute toxicity of the leaves aqueous macerate of boscia senegalensis
    Authors: Mohamed B. Belemlilga, Mathieu Nitiema, Aristide Traore, Eric Nanema, Souleymane Compaore, G. Geoffroy Ouedraogo, Sylvain Ilboudo, Lazare Belemnaba, Noufou Ouedraogo, Félix B. Kini
    Year: 2025

  3. toxicity assessment of a phytomedicine based on an almond extract from the fruit of balanites aegyptiaca intended for helminthiases care in burkina faso
    Authors: G. G. Ouedraogo, M. B. Belemlilga, T. Kouguilima, G. D. Somda, S. Ilboudo, S. Ouedraogo, A. Traore, L. Belemnaba, F. B. Kini, S. Ouedraogo
    Year: 2025

  4. acute toxicity and anthelmintic effects of gomphrena serrata extracts on adult worms and eggs of haemonchus contortus
    Authors: H. Ouedraogo, M. B. Belemlilga, A. Traore, G. A. L. Boly, F. Moyenga, G. G. Ouedraogo, S. Ilboudo, L. Belemnaba, S. Ouedraogo
    Year: 2024

  5. antibacterial, anti-inflammatory and antioxidant activities of an acazy herbal formula used in traditional medicine to treat respiratory infections
    Authors: M. B. Belemlilga, B. Bayala, G. A. L. Boly, M. A. Ouédraogo, A. R. Boina, B. Yaro, F. Badea, C. Diguti, M. Koala, D. P. Ilboudo, et al.
    Year: 2024

  6. optimization and standardization of the extraction method of balanites aegyptiaca seeds used in the formulation of an antiparasitic phytomedicine
    Authors: M. B. Belemlilga, S. Ouedraogo, G. A. L. Boly, D. H. Dao, J. T. Coulibaly, J. C. R. P. Ouedraogo, S. Compaoré, S. Traore, M. Koala, E. N. H. Youl
    Year: 2024

  7. evaluation of acute and subacute toxicity and sedative effect of feretia apodanthera leaves
    Authors: A. S. Silue, S. Ilboudo, T. A. Djadji, G. Ouedraogo, M. B. Belemlilga, G. Kouakou-Siransy, R. Semdé
    Year: 2024

  8. phytochemical profile, acute toxicity, antioxidant and anti-inflammatory activity of hydroethanolic extracts from odontonema strictum root and stem
    Authors: M. Nitiema, L. Belemnaba, C. W. R. Ouedraogo, M. B. Belemlilga, S. Ouedraogo, M. Koala, A. Traore, J. F. Aïkpe, N. Ouedraogo, F. B. Kini
    Year: 2024

  9. phytochemical and in vitro anthelmintic properties of mesocarp of fruit extracts from balanites aegyptiaca
    Author: Mohamed Bonewendé Belemlilga
    Year: 2024

Hsu-Shan Huang | Drug Development | Outstanding Scientist Award

Published on by Applied Scientist

Prof. Dr. Hsu-Shan Huang | Drug Development | Outstanding Scientist Award

Professor at Taipei Medical University, Taiwan

Dr. Hsu-Shan Huang is a distinguished professor and biomedical researcher whose career spans over three decades in academia, pharmaceutical sciences, and translational medicine. Currently serving as a Professor at the Graduate Institute of Cancer Biology and Drug Discovery and the Ph.D. Program in Biotechnology Research and Development at Taipei Medical University, he is also an Adjunct Professor at the National Defense Medical Center. Dr. Huang holds a doctorate (Dr.rer.nat.) in Pharmacy from the University of Regensburg, Germany, and has made groundbreaking contributions to cancer therapeutics, drug development, and pharmacological sciences. He has published over 70 high-impact scientific articles in internationally renowned journals and has held significant leadership positions, including Dean and Director roles at the NDMC and Chief Pharmacist at Tri-Service General Hospital. His expertise lies in structure-based drug design, computational biology, and pharmacoinformatics, with his research actively contributing to the discovery of targeted therapies for cancer, diabetes, and inflammatory diseases. Dr. Huang’s multidisciplinary collaborations across Germany, Italy, the USA, and Taiwan have amplified his impact in global pharmacological research. He is widely recognized for integrating academic rigor with applied biomedical innovation, making him a vital contributor to advancing modern therapeutic strategies in Asia and beyond.

Professional Profile

Education

Dr. Hsu-Shan Huang’s educational trajectory reflects a strong foundation in pharmaceutical sciences, built upon rigorous academic training across both national and international institutions. He began his academic journey with a Bachelor of Science in Pharmacy from the National Defense Medical Center (NDMC) in Taipei, Taiwan, in 1985. Motivated to deepen his expertise, he pursued a Master of Science degree at the Graduate Institute of Pharmacy, NDMC, graduating in 1987. His academic excellence and research curiosity led him to Germany, where he completed his Doctorate in Natural Sciences (Dr.rer.nat.) at the Institute of Pharmacy, University of Regensburg, in 1996. This doctoral program equipped him with advanced research skills and a global perspective on pharmaceutical development. Throughout his academic progression, Dr. Huang immersed himself in interdisciplinary training, combining pharmacology, drug design, and molecular biology. His international education not only broadened his scientific insights but also fostered a collaborative mindset that has become central to his professional identity. These formative experiences laid a robust foundation for a prolific research and teaching career, enabling him to contribute significantly to pharmacological sciences, particularly in cancer biology, drug discovery, and bioinformatics-driven medicine.

Professional Experience

Dr. Hsu-Shan Huang has amassed an extensive and impactful professional career, marked by leadership roles, academic appointments, and international collaborations. Since 2014, he has been serving as Professor at Taipei Medical University, contributing to both the Graduate Institute of Cancer Biology and Drug Discovery and the Ph.D. Program in Biotechnology Research and Development. His previous roles include Professor and Dean at the School of Pharmacy, NDMC, and Director of both the Department of Pharmacy Practice and the Department of Research and Development at Tri-Service General Hospital and NDMC, respectively. Dr. Huang has also held prestigious visiting positions at the University of Pavia (Italy), University of Münster (Germany), and The Scripps Research Institute (USA), highlighting his international recognition. Additionally, he served as Secretary General for the Consortium for Globalization of Chinese Medicine, demonstrating his commitment to integrating traditional and modern biomedical sciences. With a teaching and research career beginning in 1987, Dr. Huang progressed from Lecturer to Associate Professor, and then to full Professor, reflecting his consistent contributions and leadership. His career exemplifies a unique blend of academic scholarship, pharmaceutical innovation, and cross-border collaboration, significantly advancing the fields of pharmacology and biomedical research.

Research Interest

Dr. Hsu-Shan Huang’s research interests are rooted in the intersection of cancer biology, drug discovery, and computational pharmacology. His primary focus is on developing novel therapeutic strategies targeting complex diseases such as cancer, diabetes, and neuroinflammation through bioinformatics-driven drug design. He is particularly engaged in the identification of oncogenic biomarkers and the synthesis of small-molecule inhibitors that disrupt key signaling pathways involved in tumor progression, metastasis, and resistance. A significant aspect of his work includes the application of structure-based design and multi-omics analysis to uncover novel drug targets and elucidate mechanisms of drug action. Dr. Huang’s research also explores the therapeutic repurposing of bioactive compounds derived from natural sources and the development of nanomedicine-based delivery systems for targeted therapy. Collaborating globally with computational biologists, chemists, and clinicians, he contributes to preclinical evaluations of potential drug candidates across a range of cancers, including glioblastoma, ovarian, and colorectal cancers. His research aligns with current trends in precision medicine, aiming to personalize treatments based on molecular signatures. By integrating in vitro, in vivo, and in silico methodologies, Dr. Huang is at the forefront of translational science bridging lab-based discovery with clinical application.

Research Skills

Dr. Hsu-Shan Huang possesses a comprehensive repertoire of research skills that span molecular pharmacology, bioinformatics, and translational medicine. His expertise includes structure-based drug design, molecular docking, virtual screening, and multi-omics data integration—tools he employs to identify novel drug targets and evaluate therapeutic efficacy. He is proficient in using computational platforms for in silico modeling and simulation, enabling high-throughput analysis of molecular interactions and predicting pharmacokinetics and pharmacodynamics profiles. Dr. Huang is also skilled in chemical synthesis and biological evaluation of small molecules, conducting rigorous in vitro and in vivo experiments to assess anticancer, antidiabetic, and anti-inflammatory properties. He demonstrates advanced capabilities in biomarker identification, gene expression profiling, and signaling pathway elucidation through next-generation sequencing and proteomic techniques. His collaborative work often involves pharmacoinformatics-based compound optimization and target validation using cell line models, animal studies, and patient-derived samples. Additionally, Dr. Huang’s experience with nanomedicine formulation and targeted delivery systems adds a translational dimension to his skill set, enabling bench-to-bedside applications. These multidisciplinary competencies allow him to address complex biomedical challenges, contributing to the development of innovative therapies with enhanced specificity and reduced side effects.

Awards and Honors

Dr. Hsu-Shan Huang has been widely recognized for his contributions to pharmacological and biomedical sciences through numerous awards, honors, and prestigious appointments. Over the years, he has received commendations for academic excellence, leadership in pharmaceutical education, and groundbreaking research in drug discovery and translational medicine. His appointment as Professor at top-tier institutions such as Taipei Medical University and National Defense Medical Center is a testament to his professional stature. He served as Secretary General of the Consortium for Globalization of Chinese Medicine, a role highlighting his leadership in integrating traditional medicine with contemporary biomedical approaches. Dr. Huang has been invited as a visiting scientist and professor at renowned international institutes including the University of Pavia, University of Münster, and The Scripps Research Institute, reflecting the global acknowledgment of his expertise. His research articles, many of which are published in Q1 journals with high impact factors, have received significant citations, establishing his influence in the field. In addition to academic accolades, his mentorship of young scientists and leadership in research collaborations further cement his status as a respected figure in pharmacological innovation.

Conclusion

Dr. Hsu-Shan Huang’s career exemplifies the seamless integration of academic excellence, innovative research, and global collaboration in the field of pharmaceutical and biomedical sciences. With over three decades of impactful work, he has not only shaped the landscape of drug discovery and cancer biology in Taiwan but also contributed significantly to international biomedical advancements. His multidisciplinary expertise—spanning molecular pharmacology, computational biology, and translational research—positions him as a thought leader in the development of next-generation therapeutics. Dr. Huang’s contributions have bridged the gap between laboratory research and clinical application, particularly through his work on small-molecule inhibitors, nanomedicine, and biomarker-driven therapies. His dedication to mentorship and collaboration underscores his commitment to cultivating future generations of researchers. Recognized both nationally and internationally, Dr. Huang continues to push the boundaries of biomedical science with a vision centered on precision, innovation, and patient-centered outcomes. As a scholar, educator, and scientific innovator, he stands as a pillar in Taiwan’s scientific community and a valuable collaborator on the global stage.

Publications Top Notes

  1. Computer‑aided drug discovery of a dual‑target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI‑60

    • Authors: Tang S.L., Rachmawati M.S., Kuo Y.C., Hsu H.L., Ansar M., Huang S.L., Lee S.Y., Wang H.J., Lawal B., Wu A.T.H., Chen L.C., Huang H.S. et al.

    • Year: 2025

  2. Bioprospection of Hura crepitans metabolites against oxidative stress and inflammation: An in vitro and in silico exploration

    • Authors: Kuo Y.C., Lawal B., Lukman H.Y., Chen L.C., Huang S.L., Chen Y.F., Fadaka A.O., et al.

    • Year: 2025

  3. Evaluation of terpenes‑rich Hura crepitans extract on glucose regulation and diabetic complications in STZ‑induced diabetic rats

    • Authors: Lukman H.Y., Kuo Y.C., Owolabi M.S., Lawal B., Chen L.C., Ajenifujah O.T., Fadaka A.O., et al.

    • Year: 2024

    • Citations: 4

  4. Structure‑based design, synthesis and biological evaluation of N‑substituted 6H‑thiochromeno[2,3–c]quinolin‑12(12H)-one as potential breast cancer drugs

    • Authors: Rachmawati M.S., Chen L.C., Tsai W.C., Ansar M., Lawal B., Mokgautsi N., Guh J.H., Wu T.H.A., Huang H.S., et al.

    • Year: 2024

    • Citations: 1

  5. Mechanistic study of dual‑function inhibitors targeting topoisomerase II and Rad51‑mediated DNA repair pathway against castration‑resistant prostate cancer

    • Authors: Chiang Y.C., Leu W.J., Chen Y.C., Ye P.C., Hsiao Y.C., Hsu J.L., Hsu L.C., Huang H.S., Guh J.H., et al.

    • Year: 2023

  6. Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent

    • Authors: Chinyama H.A., Wei L., Mokgautsi N., Lawal B., Wu T.H.A., Huang H.S., et al.

    • Year: 2023

    • Citations: 6

  7. In Silico Evaluation of HN‑N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non‑Small Cell Lung Cancer

    • Authors: Chen L.C., Mokgautsi N., Kuo Y.C., Wu T.H.A., Huang H.S., et al.

    • Year: 2023

    • Citations: 3

  8. Multi‑Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi‑Target Agent for c‑MET/STAT3/AKT Signaling Axis

    • Authors: Mokgautsi N., Kuo Y.C., Chen C.H., Huang Y.J., Wu T.H.A., Huang H.S., et al.

    • Year: 2023

    • Citations: 6

  9. Apigetrin‑enriched Pulmeria alba extract prevents assault of STZ on pancreatic β‑cells and neuronal oxidative stress with concomitant attenuation of tissue damage and suppression of inflammation in the brain of diabetic rats

    • Authors: Rachmawati M.S., Chen L.C., Tsai W.C., Ansar M., Lawal B., Mokgautsi N., Guh J.H., Wu T.H.A., Huang H.S., et al.

    • Year: 2023

    • Citations: 8

  10. In silico study of novel niclosamide derivatives, SARS‑CoV‑2 nonstructural proteins catalytic residue‑targeting small molecules drug candidates

    • Authors: Lawal B., Tsai S.K., Wu T.H.A., Huang H.S., et al.

    • Year: 2023

    •  Citations: 3

Shijia Lu | Medical Discoveries | Best Researcher Award

Published on by Applied Scientist

Mr. Shijia Lu | Medical Discoveries | Best Researcher Award

Sanquan College of Xinxiang Medical University, China

Shijia Lu is an emerging biomedical researcher and Associate Editor of the Guide to Biomedical Research Tools, affiliated with Sanquan College of Xinxiang Medical University. With a foundational academic background in Biotechnology, she has focused her expertise on tumor-targeted therapy and drug resistance mechanisms. As a Student Member of the Chinese Society for Biotechnology, she actively contributes to bridging computational biology with clinical oncology. Her research integrates network pharmacology, molecular dynamics, and in silico simulations to explore anti-cancer drug discovery. Shijia has led and participated in several significant research projects, including a Henan Province Science and Technology Innovation initiative. Her contributions as first author to a peer-reviewed SCI journal article on PCNA-targeted inhibitors have drawn national recognition. She has won three national research awards and two provincial translation honors, reflecting her interdisciplinary proficiency. Known for developing dual-ligand inhibitors that counteract mutation-based resistance, her work has received acclaim in innovation competitions and scientific circles alike. Passionate about leveraging bioinformatics for real-world medical challenges, Shijia promotes tool-based translational cancer research through editorial leadership. Her professional trajectory demonstrates a strong commitment to advancing oncology therapeutics through an integrative and experimental lens, making her an excellent candidate for the Young Scientist Award.

Professional Profile

ORCID Profile

 Education

Shijia Lu holds a Bachelor’s degree in Biotechnology from Sanquan College of Xinxiang Medical University, where she built a solid foundation in the molecular and cellular mechanisms underpinning disease, especially cancer. During her academic tenure, she distinguished herself by merging theoretical coursework with hands-on laboratory research, focusing on tumor biology and pharmacological interventions. Her keen interest in bioinformatics led her to independently master essential research software such as AutoDock Vina, STRING, Cytoscape, and others, allowing her to translate genomic and proteomic data into therapeutic insights. As part of her academic progression, she actively engaged in university-sponsored research competitions and projects that emphasized the intersection of computational biology and experimental science. Her education was not confined to the classroom—she collaborated across departments on interdisciplinary initiatives, strengthening her expertise in network pharmacology, molecular simulation, and drug-target interaction studies. Her early exposure to grant-funded projects and her participation in the Henan Province Science and Technology Innovation Program further solidified her academic profile. With a rigorous academic background paired with a practical grasp of translational biomedical research, Shijia Lu is well-prepared for a long-term career in developing innovative solutions for drug-resistant cancer therapies.

 Professional Experience

Shijia Lu has cultivated an impressive blend of editorial, research, and project leadership experience. Currently serving as the Associate Editor of the Guide to Biomedical Research Tools, she curates and reviews innovative bioinformatics and molecular biology tools for cancer research, aiding scientists across disciplines. Beyond editorial responsibilities, Shijia has actively led three major university-level research projects and collaborated on a province-level scientific initiative, demonstrating both autonomy and teamwork in research execution. Her landmark role as Principal Investigator on the 2025–2026 PCNA-targeted inhibitor project marks a high point in her professional experience, where she designed dual-ligand molecules to overcome drug resistance mutations. She also oversaw the development of a patented anti-tumor drug screening system, highlighting her capacity for product-oriented research. Her consultancy work in national innovation contests, where she secured second place for a novel cancer treatment strategy, further underscores her practical contributions. Shijia’s experience spans laboratory-based experimental verification, high-level simulation, and tool development. Her engagement in both academic and translational science demonstrates a maturity beyond her years, making her an asset to collaborative biomedical innovation. Her multifaceted career blends scientific rigor with editorial insight, contributing meaningfully to cancer research advancement.

Research Interest

Shijia Lu’s research is deeply rooted in the mechanisms of tumor-targeted therapy and overcoming resistance through computational and experimental synergy. She is particularly interested in how network pharmacology, molecular docking, and bioinformatics can converge to inform drug discovery for aggressive cancers. Her ongoing work explores PCNA (Proliferating Cell Nuclear Antigen) as a pivotal target in anticancer therapy, focusing on its mutations, druggability, and protein interaction networks. Shijia leverages cutting-edge tools such as ESM-Fold, MM/GBSA simulations, and AutoDock Vina to identify novel compounds and validate them through simulation-driven predictions. Her interdisciplinary curiosity extends to toxicogenomics, as seen in her research on ribavirin-induced hemolytic anemia. A key facet of her research interest is “multi-dimensional synergy,” a concept she introduced to integrate dual-ligand designs and structural-functional coupling strategies. She also utilizes multi-omics datasets to pinpoint plant-derived bioactives, such as from pomegranate peel, offering eco-sustainable therapeutic options. This combination of wet-lab experiments and dry-lab modeling makes her approach both innovative and pragmatic. Shijia’s vision is to bridge in silico drug design with clinical applicability, ultimately reducing trial costs and improving therapeutic precision. Her research ambition is to contribute meaningfully to the fight against cancer by creating data-validated, mutation-resistant therapeutic options.

 Research Skills

Shijia Lu possesses an advanced set of interdisciplinary research skills that span computational biology, molecular pharmacology, and bioinformatics. She is proficient in molecular docking (AutoDock Vina), protein interaction analysis (STRING), pathway visualization (Cytoscape), and structure prediction (ESM-Fold). These skills have enabled her to develop innovative inhibitors, simulate their interactions under mutation conditions, and validate their potential efficacy in silico. Her command over MM/GBSA free energy calculations has been crucial in quantifying ligand-protein binding affinities in mutation scenarios. Beyond software, she is experienced in network pharmacology frameworks, toxicogenomic analysis, and data-driven compound screening, using multi-omics datasets to identify phytochemicals for anti-cancer properties. Shijia is also skilled in designing and conducting wet-lab experiments, including molecular cloning and cell-based assays, for validating computational predictions. Her capabilities extend to scientific writing, patent filing, and data visualization—key components that have facilitated her publication in an SCI-indexed journal and the development of a research reference book. Furthermore, her leadership as a principal investigator in multiple research projects shows her competence in proposal writing, budget management, and collaborative project execution. Her comprehensive skill set equips her to tackle multifaceted biomedical challenges and positions her as a strong contributor to translational cancer research.

Awards and Honors

Shijia Lu has received multiple prestigious recognitions that affirm her contributions to biomedical research and innovation. She is the recipient of three national-level awards from competitive research and innovation contests in the medical health category, including second place at the Fourth National College Students’ Innovation and Entrepreneurship Competition. Her project, “A New Anti-Cancer Strategy Targeting PCNA,” earned national acclaim for its novel approach to overcoming drug resistance using dual-ligand inhibitors. Additionally, she has won two provincial awards for excellence in scientific translation, demonstrating her ability to convey complex biomedical content across languages—a skill vital in international research collaboration. Shijia has also been recognized through institutional grants and provincial-level research sponsorships, such as the Henan Province Science and Technology Innovation Project (No: 252102310194), for which she played a leading role in experimental verification. Her achievements extend to academic publishing, with her first-author SCI paper being widely cited and referenced in cancer pharmacology studies. These accolades reflect her exceptional interdisciplinary capacity, scientific communication proficiency, and innovative mindset. Through consistent recognition at institutional, provincial, and national levels, Shijia Lu has proven herself a rising leader in biomedical research deserving of the Young Scientist Award.

Conclusion

In summary, Shijia Lu exemplifies the ideal profile of a young and dynamic biomedical researcher dedicated to tackling some of the most pressing challenges in oncology. With a robust academic background, hands-on project leadership, and deep technical skills in computational drug design and network pharmacology, she has already made notable contributions to the field of tumor-targeted therapy. Her research on PCNA-targeted inhibitors has not only earned her national recognition but also holds translational promise in overcoming cancer drug resistance. As an Associate Editor and an active member of academic societies, Shijia promotes interdisciplinary collaboration and innovation. Her commitment is evident in her editorial work, her numerous research outputs, and her continuous quest for merging digital simulation with practical experimentation. Through her combination of creativity, technical mastery, and academic leadership, she represents the new generation of scientists driving biomedical progress forward. With several national awards and published research to her credit, she is poised to contribute significantly to future breakthroughs in cancer treatment. For her excellence in research, leadership potential, and impactful contributions.

Publications Top Notes

Title:
Design and Anti-Drug Resistance Research of Novel PCNA-Targeted Inhibitors Based on Network Pharmacology and Molecular Docking

Authors:
Shijia Lu, YiRan Zhen, Jinwen Sima, Jinle Wang, Qihao Zhu, Miaoyan Han, Mengdan Sang, Xuejiao Li, Bing Zhang, Zihan Wang, et al.

Year:
2025

Zecong Xiao | Precision Medicine | Best Researcher Award

Published on by Applied Scientist

Assoc. Prof. Dr. Zecong Xiao | Precision Medicine | Best Researcher Award

Associate Research Fellow at The Third Affiliated Hospitial of Sun Yat sen University, China

Dr. Zecong Xiao is a distinguished Associate Research Fellow and Master’s Supervisor at the Nanomedicine Center, The Third Affiliated Hospital of Sun Yat-sen University. As a recognized member of Sun Yat-sen University’s prestigious “Hundred Talents Program” for Young Talents, Dr. Xiao is known for his pioneering research in nanomedicine, tumor immunotherapy, and tissue engineering. Born on January 5, 1992, he has swiftly risen through the academic ranks, demonstrating a strong commitment to translational biomedical research. His scientific contributions are substantiated by an H-index of 24 and over 1,900 citations. Dr. Xiao has published 49 SCI-indexed articles, with 41 of them as first or corresponding author in high-impact journals like Science Advances, ACS Nano, Bioactive Materials, and Signal Transduction and Targeted Therapy. He has effectively integrated interdisciplinary strategies in engineering, pharmacology, and immunotherapy to advance cancer treatment methodologies. Beyond his publication record, he has served as a principal investigator in numerous national and provincial research grants, with total funding exceeding 2 million RMB. His ongoing commitment to innovation, mentoring, and collaborative science positions him as a prominent thought leader in applied biomedical research in China and beyond.

Professional Profile

Education

Dr. Zecong Xiao has received comprehensive academic training across multiple disciplines relevant to pharmaceutical and biomedical research. He earned his Ph.D. in Engineering with a focus on Materials Science from Sun Yat-sen University in June 2020, where he initiated his foundational research into drug delivery systems and nanomedicine. His doctoral work equipped him with interdisciplinary expertise blending materials science, pharmacology, and immunotherapy—areas central to his current research pursuits. Prior to his doctoral studies, he completed a Master’s degree in Medicine with a specialization in Pharmacology at Wenzhou Medical University in 2017. This phase of his education provided a critical understanding of drug mechanisms and therapeutic interventions at the cellular and systemic levels. Dr. Xiao began his academic journey with a Bachelor of Science in Pharmacy from Jiangxi University of Chinese Medicine in 2014, grounding him in pharmaceutical sciences and traditional Chinese medicine. Each phase of his education not only broadened his technical skills but also deepened his commitment to translational research, laying a strong foundation for his contributions to cancer immunotherapy and advanced drug delivery technologies. His academic background showcases a rare integration of pharmacological principles and engineering applications.

Professional Experience

Dr. Zecong Xiao currently serves as an Associate Research Fellow and Master’s Supervisor at the Nanomedicine Center of The Third Affiliated Hospital of Sun Yat-sen University. Since March 2023, he has been actively involved in cutting-edge research focused on nanodrug delivery, tumor-targeting immunotherapy, and tissue engineering repair. His role involves supervising graduate students, leading national and university-level research projects, and publishing high-impact papers. Before this, from August 2020 to August 2022, Dr. Xiao completed a productive postdoctoral fellowship at The Second Affiliated Hospital of Guangzhou Medical University. During this period, he developed a number of innovative nanomedicine strategies for targeted cancer therapy, earning national-level funding and recognition. Dr. Xiao’s professional experience reflects a trajectory of consistent scientific growth, marked by deep collaborations across disciplines such as bioengineering, immunology, and clinical oncology. His participation in multi-million RMB projects, both as principal investigator and key contributor, highlights his strategic thinking and leadership. At every career stage, he has demonstrated a clear vision for applying laboratory innovation to clinical contexts. His position in Sun Yat-sen’s “Hundred Talents Program” further affirms his status as a rising star in translational biomedical research in China.

Research Interest

Dr. Zecong Xiao’s research interests lie at the dynamic interface of nanomedicine, immunotherapy, and materials science. His work is primarily focused on the design and development of smart drug delivery systems that can effectively target tumors and modulate the immune microenvironment for enhanced therapeutic efficacy. He is particularly interested in functional nanomaterials that can bypass biological barriers to deliver payloads such as siRNA, small molecules, and proteins directly to diseased tissues. Dr. Xiao’s lab explores methods for improving T-cell infiltration into solid tumors using bioorthogonal nanodrug strategies and CAR-T cell modifications. He is also deeply involved in the study of tumor interstitial pressure and how to engineer delivery platforms that overcome this hurdle. Recently, his research has expanded into tissue engineering and regenerative medicine, with projects investigating hydrogel-based scaffolds and MOF-based delivery systems for spinal cord injury and wound healing. His translational approach aims to bridge the gap between fundamental materials science and clinical applications in oncology and regenerative therapy. Overall, Dr. Xiao’s interdisciplinary focus on applying nanoscale innovations to solve complex biomedical problems situates him at the forefront of next-generation therapeutic development.

Research Skills

Dr. Zecong Xiao possesses an extensive and advanced skill set that supports his multidisciplinary research in nanomedicine and cancer immunotherapy. He is proficient in the synthesis and characterization of functional nanomaterials, including stimuli-responsive nanoparticles, metal-organic frameworks (MOFs), and hydrogel-based delivery systems. He demonstrates expertise in drug encapsulation techniques, bioorthogonal chemistry, and surface functionalization, which are critical for targeted delivery and controlled release. Dr. Xiao is also well-versed in various in vitro and in vivo experimental models, enabling comprehensive evaluation of therapeutic efficacy and biocompatibility. His ability to integrate imaging technologies such as fluorescence microscopy and ultrasound enhances his work in biodistribution and real-time tracking of nanodrugs. In immunological applications, he is skilled in flow cytometry, ELISA, cytokine profiling, and T-cell modification techniques such as CAR-T engineering. Computational modeling and statistical analysis are further tools he utilizes for experimental design and data interpretation. In addition to laboratory competencies, Dr. Xiao has demonstrated proficiency in academic writing, grant proposal development, and project management, contributing to his success in securing multiple national research grants. Collectively, these skills empower him to conduct high-impact, translational research aimed at improving clinical outcomes in oncology and tissue regeneration.

Awards and Honors

Dr. Zecong Xiao has earned significant recognition for his research contributions, highlighted by his selection into the prestigious “Hundred Talents Program” at Sun Yat-sen University—a testament to his exceptional promise as a young scientist. This competitive initiative supports top-tier early-career researchers, offering substantial research funding and institutional support. He has also received the First-Class Grant from the China Postdoctoral Science Foundation, acknowledging his groundbreaking work on matrix clearance-based nanodelivery systems to improve T-cell tumor infiltration. Dr. Xiao has served as Principal Investigator on multiple nationally and provincially funded projects, including grants from the National Natural Science Foundation of China and the Guangdong Provincial Science Fund for Applied Basic Research. His cumulative research funding exceeds 2 million RMB, reflecting the strong institutional and governmental trust in his work. In addition to funding awards, his published works have garnered widespread academic acclaim, accumulating over 1,900 citations and an H-index of 24—extraordinary achievements for a researcher of his age. His papers frequently appear in top-tier journals with impact factors exceeding 10, further underscoring the innovation and relevance of his research in the global scientific community.

Conclusion

Dr. Zecong Xiao exemplifies the next generation of translational researchers, leveraging multidisciplinary expertise to address some of the most pressing challenges in medicine. Through a strong foundation in materials science, pharmacology, and nanotechnology, he has developed innovative solutions for cancer immunotherapy and tissue engineering. His prolific academic output—comprising 49 high-impact publications and a rapidly growing citation record—reflects both the depth and breadth of his contributions. As a core member of Sun Yat-sen University’s “Hundred Talents Program,” he continues to inspire through mentorship, collaboration, and leadership in scientific research. His success in securing major research grants highlights both his visionary research goals and his strategic planning capabilities. With demonstrated excellence in both fundamental science and clinical translation, Dr. Xiao is poised to make lasting contributions to global healthcare, particularly in oncology, regenerative medicine, and nanomedicine. His career trajectory is a powerful example of how dedicated research, supported by institutional trust and personal perseverance, can drive scientific innovation with real-world impact. As his research continues to evolve, Dr. Xiao is set to remain at the forefront of biomedical discovery and application.

Publications Top Notes

1. Title: Endothelia-targeting eye drops deliver a STING inhibitor to effectively reduce retinal neovascularization in ischemic retinopathy
Authors: Siying Wen, Xuemin He, Jiachen Wang, Zheyao Wen, Heying Ai, Mengyin Cai, Yi Yang, Hejun Li, Shasha Li, Guojun Shi, Aimin Xu, Zecong Xiao, Xintao Shuai
Year: 2025

2. Title: Targeting m6A demethylase FTO to heal diabetic wounds with ROS-scavenging nanocolloidal hydrogels
Authors: Xinyao Zheng, S.Z. Deng, Yuan Li, Zhipeng Luo, Ziqi Gan, Zheng Zhang, Rui Xu, Shan Xiao, Yuxiong Cai, Jiazheng Meng, Li Li, Changxing Li, Xianghong Xue, Wei Dai, Qin Si, Mengying Wang, Kang Zeng, Zecong Xiao, Lai-Xin Xia
Year: 2025
Citations: 2

3. Title: A dissolvable microneedle platform for the delivery of tumor-derived total RNA nanovaccines for enhanced tumor immunotherapy
Authors: Jiachen Wang, Siying Wen, Yujie Jiang, Zheyao Wen, Minghao Zhang, Yuchen Li, Jujian Ye, Zecong Xiao, Xintao Shuai
Year: 2025

4. Title: A PD-L1 siRNA-Loaded Boron Nanoparticle for Targeted Cancer Radiotherapy and Immunotherapy
Authors: Shaohui Deng, Lijun Hu, Guo Chen, Jujian Ye, Siying Wen, Zecong Xiao, Xintao Shuai
Year: 2025
Citations: 2

5. Title: Tertiary lymphoid structure formation induced by LIGHT-engineered and photosensitive nanoparticles-decorated bacteria enhances immune response against colorectal cancer
Authors: Lijun Hu, Tan Li, Shaohui Deng, Honglin Gao, Yujie Jiang, Qiu Chen, Hui Chen, Zecong Xiao, Xintao Shuai, Zhongzhen Su
Year: 2025
Citations: 4